Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

186 results about "Peripheral blood cell" patented technology

Peripheral blood cells are the cellular components of blood, consisting of red blood cells (erythrocytes), white blood cells (leucocytes), and platelets, which are found within the circulating pool of blood and not sequestered within the lymphatic system, spleen, liver, or bone marrow.

Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same

Markers of multiple sclerosis and methods and kits utilizing same for diagnosing multiple sclerosis in an individual are provided.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD +1

Microscopic multispectral marrow and its peripheral blood cell auto-analyzing instrument and method

An analyser which comprises light source, microscope, display planar array CCD and computer is featured as the follows: a) filtering system, electric-tuning filter controller and planar CCD are disposed on microscope for quick collection of optical spectrum image, computer is used to change central frequency of band-pass; b) a CCD control and data collection system is used to store digital image into computer for image process and analysis; c) a three-dimensional movable control system is used to realize automatic focusing and scanning and d) a computer is used to carry on image composition, image calibration, automatic division and identification.
Owner:WUHAN UNIV

Leukocyte five-classification method based on deep learning

The invention belongs to the field of medical image processing, and relates to a five-classification technology for leukocytes in a human peripheral blood cell image, particularly to a leukocyte five-classification method based on deep learning. According to the leukocyte five-classification method, leukocytes are detected from a microscope image by using simple color-component relationships and morphological operations, basophils and eosinophils are identified by using particle characteristics and SVM, the remaining cell image characteristics are automatically extracted by using a convolutional neural network, and finally the remaining three-classification is achieved by using random forest. With the leukocyte five-classification method of the present invention, the errors caused by segmentation in the traditional method can be avoided, the leukocyte five-classification problem can be effectively solved, and the cells in different databases can achieve the good classification results.
Owner:CHINA JILIANG UNIV +1

Negative correlation between IRP-2 and Transferrin receptor expression as a diagnostic of Alzheimer's disease

A method of diagnosing Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) is disclosed which was identified by the fact that an increased level of iron regulating protein-2 (IRP-2) was identified in Alzheimer's patients. Further, diseases of increased cellular metabolism such as cancer showed high levels of both IRP-2 and transferrin receptor. This suggests that, in diseases of increased cellular metabolism, both aspects of iron accumulation are highly expressed, while in Alzheimer's disease only IRP-2 is highly expressed. From these results, a non-invasive test for Alzheimer's disease may be produced using patient samples containing peripheral blood cells and identifying the level of expression of IRP-2 and Transferrin receptor. Those patients which: 1. over-express IRP-2 as compared with normal controls, and 2. have comparable levels of Transferrin receptor expression to normal controls, can be identified as having or prone to AD and MCI. Further, it can be envisioned that this may be used for further diagnosis and staging of cancers of the blood.
Owner:LOMA LINDA UNIV MEDICAL CENT

Diagnosis of disease and monitoring of therapy using gene expression analysis of peripheral blood cells

Disclosed are methods to diagnose a patient that has a pulmonary disease, and particularly, pulmonary arterial hypertension, using biomarkers that are differentially regulated in the peripheral blood cells of patients with such disease as compared to individuals that do not have the disease. Also disclosed are methods to diagnose a patient that has idiopathic pulmonary arterial hypertension as compared to pulmonary arterial hypertension associated with secondary causes. Pluralities of nucleotides and antibodies useful in the invention are described. Methods of identifying compounds with the potential to treat pulmonary arterial hypertension (PAH) are also described.
Owner:UNIV OF COLORADO THE REGENTS OF

Internally administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient

Intravenous administration of bone marrow cells collected from rat bone marrow to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.
Owner:NC MEDICAL RES +2

Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient

InactiveUS20060210544A1Easily and safely obtainedInhibit ischemic damageBiocideGenetic material ingredientsDiseaseCord blood stem cell
Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.
Owner:NC MEDICAL RES

Kit for processing human marrow, cord blood and peripheral blood cells and cell processing method

InactiveCN101638637ASmall liquid volumeReduce volumeTissue cultureHuman bodyHydroxyethyl starch
The invention relates to a kit for processing human marrow, cord blood and peripheral blood stem cells and a stem cell processing method. The kit radically solves the problems of high manufacture cost, low cell activity, indefinite reaction of markers in a human body, mobilizing agent injection causing patient pain, long obtainment time, complication, clinical unsuitability, and the like in the prior cell separation technology. The invention has the technical scheme that the kit comprises the following three reagents: (1) a diluent comprising 0.9 percent of sodium chloride injection or PBS solution, (2) a precipitator comprising 6 percent of hydroxyethyl starch or 0.2-1 percent of methyl cellulose and (3) a separating solution which has the density of 1.074-1.076 and is prepared by saccharosan and diatrizoate. The kit is easy to store and transport and convenient and rapid to use and can be produced in industrialization.
Owner:BEI ZHENG STEM CELLS BIOLOGICAL TECH CO LTD BEIJING

Detection, prevention, and treatment systems for anthrax

A highly efficient method for generating human antibodies using recall technology is provided. In one aspect, human antibodies which are specific to the anthrax toxin are provided. In one aspect, human peripheral blood cells that have been pre-exposed to anthrax toxin are used in the SCID mouse model. This method results in high human antibody titers which are primarily of the IgG isotype and which contain antibodies of high specificity and affinity to desired antigens. The antibodies generated by this method can be used therapeutically and prophylactically for preventing or treating mammals exposed to anthrax. Thus, in one embodiment, a prophylactic or therapeutic agent used to counter the effects of anthrax toxin, released as a mechanism of bioterrorism, is provided. In one embodiment, a formulation and method for preventing and / or treating anthrax infection comprising a binding agent that prevents the assembly of the PA63 heptamer is also provided. Methods for diagnosis and methods to determine anthrax contamination are also described.
Owner:EMERGENT PROD DEV GAITHERSBURG INC

Methods for facilitating recovery of functions of endogenous or implanted or transplanted stem cells using hyaluronic acid

InactiveUS20060069064A1Lower Level RequirementsImproving overall in vivo microenvironmental nicheOrganic active ingredientsBiocideAdjuvantCell-Extracellular Matrix
Hyaluronic Acid (HA) is an essential component of tissue extracellular matrices that contributes to the architecture of stem cell niches, which determine the fate of stem cells. Decreased levels of HA are found in subjects experiencing a variety of pathological conditions, as well as in subjects receiving a variety of therapeutic interventions, for example, chemotherapy or radiotherapy, to treat pathological conditions. The use of HA to reconstitute a tissue extracellular matrix partially or completely depleted of HA is described. More particularly, described herein is the use of exogenous forms of HA as an adjuvant in the restoration of the local tissue specific stem cell microenvironment to enhance stem cell recovery or engraftment and thus tissue recovery and remodeling following stem cell transplantation or other therapies. The effect of HA on hematopoietic stem cells is illustrative of the invention. Mice having severe bone marrow hypoplasia, and pancytopenia resulting from treatment with 5-fluorouracil recovered more rapidly if treated with HA. Similarly, mice transplanted with hematopoietic stem cells following lethal irradiation exhibited enhanced recovery of peripheral blood cell counts when treated with HA as an adjuvant therapy compared to control mice transplanted with hematopoietic stem cells without adjuvant therapy.
Owner:LA JOLLA INST FOR MOLECULAR MEDICINE

Method for detecting anti-CD19 chimeric antigen receptor T cell effects of inhibiting leukemia cells

The invention discloses a method for detecting anti-CD19 chimeric antigen receptor T cell effects of inhibiting leukemia cells. The method comprises 1, mixing anti-CD19 chimeric antigen receptor T cells and leukemia cells according to a certain ratio, and transplanting the mixed cells into an immunodeficient mouse model, wherein the anti-CD19 chimeric antigen receptor T cell has an accession number of CCTCC NO: C201503, 2, carrying out immunodeficient mouse model peripheral blood cell dyeing, and 3, detecting the dyed peripheral blood cells by a flow cytometer. Human leukemia cells and leukemia cell inhibition cells are transplanted into an immunodeficient mouse model together so that effects of inhibiting different human leukemia cells can be really shown and high effectiveness and accuracy of the inhibition effect detection method are guaranteed.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI

Biomarker panels for assessing radiation injury and exposure

Methods and kits are provided for assessing radiation injury and exposure in a subject. The methods comprise measuring the levels of at least two (2) protein biomarkers from different biological pathways and correlating the levels with an assessment of radiation injury and exposure. Additional use of peripheral blood cell counts and serum enzyme biomarkers, evaluated in the early time frame after a suspected radiation exposure, and use of integrated multiple parameter triage tools to enhance radiation exposure discrimination and assessment are also provided. The information obtained from such methods can be used by a clinician to accurately assess the extent of radiation injury / exposure in the subject, and thus will provide a valuable tool for determining treatment protocols on a subject by subject basis.
Owner:THE HENRY M JACKSON FOUND FOR THE ADVANCEMENT OF MILITARY MEDICINE INC

Isolated myeloid-like cell populations and methods of treatment therewith

InactiveUS20070231306A1BiocideSenses disorderCD33Mammal
The present invention provides an isolated myeloid-like cell population comprising a majority of cells that are lineage negative, and which express both CD44 antigen, CD11b antigen, and hypoxia inducible factor 1α (HIF-1α). These cells have beneficial vasculotrophic and neurotrophic activity when intraocularly administered to the eye of a mammal, particularly a mammal suffering from an ocular degenerative disease. The myeloid-like cells are isolated by treating bone marrow cells, peripheral blood cells or umbilical cord cells with an antibody against CD44 (hyaluronic acid receptor), against CD11b, CD14, CD33, or against a combination thereof and using flow cytometry to positively select CD44 and / or CD11b expressing cells therefrom. The isolated myeloid-like bone marrow cells of the invention can be transfected with a gene encoding a therapeutically useful protein, for delivering the gene to the retina.
Owner:THE SCRIPPS RES INST

Method of providing readily available cellular material derived from peripheral blood, and a composition thereof

The present invention is directed to the TVEMF-expansion of mammalian peripheral blood stem cells, preferably CD34+ / CD38− cells, to compositions resulting from the TVEMF-expanded cells, and to a method of treating disease or repairing tissue with the compositions.
Owner:REGENETECH INC

Methods and reagents for quantitation of cell-surface molecule expression on peripheral blood cells

Improved methods, reagents, and kits for quantitation of HLA-DR and / or CD11b expression on peripheral blood cells are presented. Inclusion of a lysosomotropic amine, such as chloroquine, during staining stabilizes HLA-DR and CD11b expression. Use of a novel anti-CD14 conjugate, anti-CD14-PerCP / CY5.5, permits the ready discrimination of monocytes. The improved methods, reagents, and kits may be used to assess immune competence, and to direct and monitor immunostimulatory therapies in septic patients exhibiting monocyte deactivation.
Owner:BECTON DICKINSON & CO

Methods of diagnosing cancer

A method of diagnosing cancer or a pre-malignant lesion is disclosed. The method comprises determining a level of CD24 expressed on peripheral blood cells of a subject in need thereof, wherein the level of CD24 above a predetermined threshold is indicative of the cancer or the pre-malignant lesion.
Owner:THE MEDICAL RES INFRASTRUCTURE & HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENT

Human marrow, cord blood or peripheral blood stem cells treating kit and stem cells separating method

InactiveCN102154201AStrong targetingIncrease the amount of separation and recoverySkeletal/connective tissue cellsBlood/immune system cellsPeripheral blood cellCord blood sample
The invention relates to a human marrow, cord blood or peripheral blood stem cell treating kit and a stem cell separating method. The kit consists of liquid 1, liquid 2 and liquid 3. Based on the prior art, brain protein hydrolysate is added into the liquid 1, so that the stem cells recovery quantity of the treating sample is effectively improved. The kit is used for separating the human marrow from the cord blood or the peripheral blood. Aiming at a cord blood sample, the separated cell recovery sum is improved by 5.9-15.8%, and the separated CD34 stem cell recovery sum is improved by 5.0-8.8%; aiming at a marrow sample, the separated cell recovery sum is improved by 8.7-21%, and the separated CD34 stem cell recovery sum is improved by 8.4-11%; and aiming at a peripheral blood sample, the separated cell recovery sum is improved by 23.1-46.7%, and the separated CD34 stem cells recovery sum is improved by 10.8-25.6%. Due to the improvement of the target stem cells separating and recovering ratio, the human marrow samples, cord blood samples or peripheral blood stem cell samples can be effectively saved, and the use efficiency of the samples can be improved.
Owner:唐明淇

Stimulator of stem cell division

Disclosed and claimed are methods for the isolation and use of stem cell modulating factors for regulating stem cell cycle and for accelerating the post-chemotherapy peripheral blood cell recovery. Also disclosed and claimed are the inhibitors and stimulators of stem cell proliferation.
Owner:WELLSTAT THERAPEUTICS

Method for detecting relative gene polymorphism of warfarin personalized medication by using high-resolution melting curve analysis technology

The invention discloses a method for detecting relative gene polymorphism of warfarin personalized medication by using a high-resolution melting curve analysis technology. The method is characterized by comprising the following steps: adopting a silica gel adsorption method to extract genome DNA (Deoxyribose Nucleic Acid) of an oral epithelial cell / peripheral blood cell sample of a detected person; designing a detection primer containing a target site; carrying out site typing on a PCR (Polymerase Chain Reaction) amplified gene sequence by using the high-resolution melting curve (HRM) analysis technology. The method disclosed by the invention is high in sensitivity, good in specificity and fast in detection speed, and can be used for providing reference to a clinical medication dosage of warfarin, so as to realize reasonable and effective personalized medication.
Owner:上海中优医药高科技股份有限公司

Method for detecting PAH (Polycyclic Aromatic Hydrocarbon) gene mutation by utilizing high-resolution melting curve analysis technique

InactiveCN103509865AQuick screeningFacilitate the establishment of early diagnosisMicrobiological testing/measurementPhenylalanine hydroxylaseExon
The invention discloses a method for detecting PAH (Polycyclic Aromatic Hydrocarbon) gene mutation by utilizing a high-resolution melting curve analysis technique. The method is characterized by comprising the following steps: adopting a silica gel adsorption method to extract the genome DNA of an oral epithelial cell / peripheral blood cell sample of a detected person, designing the third, sixth, seventh, eleventh and twelfth exon sequences of the PAH gene as detection primers of a template, and carrying out mutation detection on the gene sequences after PCR (Polymerase Chain Reaction) amplification according to the high-resolution melting curve analysis technique. The method has the advantages of high sensitivity, good specificity and high detection speed and can quickly screen common mutation sites of phenylalanine hydroxylase genes. The invention provides a new basis for the method for detecting PAH gene mutation.
Owner:上海中优医药高科技股份有限公司

Subfamily distant hybridization for German mirror carp and megalobrama amblycephala and application of tetraploid hybrid fishes

The invention discloses a subfamily distant hybridization for German mirror carp and megalobrama amblycephala. The method comprises the following steps of artificial dry-process fertilization on the ova of the pubescent German mirror carp and sperms of the megalobrama amblycephala by taking the German mirror carp as a female parent and the megalobrama amblycephala as a male parent, hatching fertilized ova at the water temperature of 19-20 DEG C, and breeding fries in a pond; then, detecting the DNA (deoxyribonucleic acid) content, the chromosome number and the blood cell sizes of the fries by a flow cytometry DNA content determination method, a chromosome ploidy detection method of peripheral blood cell culture and a blood smear method, screening, and then preparing to obtain triploid hybrid fishes and tetraploid hybrid fishes. A tetraploid fish strain which is genetically stable and has four sets of crucian carp chromosomes can be formed by subsequent self-cross selective breeding of the tetraploid hybrid fishes, and the tetraploid fish strain can be used as a resource for breeding the infertile triploid fishes. The method disclosed by the invention has the advantages that not only are the characters of hybrid offspring good but also a good foundation can be laid for variety breeding, and a precious resource is provided for subsequent breeding of new polyploid fishes.
Owner:湖南岳麓山水产育种科技有限公司

Detection kit and detection method for methylation of septin9 gene in human peripheral blood cell-free DNA

InactiveCN105861672ASmall sample lossThe method is simple, fast and economicalMicrobiological testing/measurementReference genesCell free
The invention belongs to the field of biomedicine, and provides a detection kit and a detection method for methylation of septin9 gene in human peripheral blood cell-free DNA. The kit comprises a primer sequence corresponding to a septin9 gene methylation detection site, a septin9 gene detection site probe sequence, a primer sequence corresponding to a reference gene detection site, and a reference gene detection site probe sequence, wherein the septin9 gene detection site is one site of septin9 gene CpG island 3, and the reference gene is Actin. The design and result reading of the detection kit provided by the invention are simple and convenient in the whole detection flow, and the detection result is reliable and high in specificity and sensitivity. By carrying out enzymolysis of cell-free DNA for detection of methylation of the septin9 gene, the sample loss is small. The method is simple, quick, economical and practical. The detection kit and detection method can be used for assisting in screening and diagnosis of carcinoma of large intestine, and further improving the cure rate and lowering death rate.
Owner:杭州壹锋生物科技有限公司

Kit for treating human bone marrow, umbilical cord blood, and peripheral blood cells, and cell treatment method

The invention discloses a kit for treating human bone marrow, umbilical cord blood, and peripheral blood cells, and provides a kit for treating human bone marrow, umbilical cord blood, and peripheral blood cells and a cell treatment method which are strong in operationality, high in clinical safety, and convenient for clinical popularization. The kit comprises four reagents: No. A liquid is a diluent; No. B liquid is density fluid; No. C liquid is washing liquid; No. D liquid is erythrocyte-removing liquid. The invention fundamentally solves the problems of high cost, low cell activity, undefined human body influence for markers entering human body, pain for patients due to mobilization agent injection, cumbersome and inapplicable operations, and the like for current cell separation technology.
Owner:WUHAN HAMILTON BIOTECH

Cultivation method of gynogenesis megalobrama amblycephala

The invention discloses a cultivation method of a gynogenesis megalobrama amblycephala, which comprises the following steps of: firstly selecting and breeding a female megalobrama amblycephala and a male erythroculter ilishaeformis bleeker as parent fishes; then carrying out artificial induced spawning to obtain the sperms of the erythroculter ilishaeformis bleeker and the ripe ovums of the megalobrama amblycephala; mixing the erythroculter ilishaeformis bleeker sperms inactivated by ultraviolet rays with the ripe ovums of the megalobrama amblycephala; 3-4 minutes later, placing the ovums activated at 0-4 DEG C for cold shock treatment for 20-30 minutes; and after incubating embryos treated by cold shock at 23-24 DEG C, obtaining diploid gynogenesis megalobrama amblycephalas through a flow type cell DNA content determination method and a chromosome ploidy detection method of peripheral blood cell culturing. The cultivation method of the gynogenesis megalobrama amblycephala has the advantages of short cultivation time, fast growth speed, high incubation rate, excellent offspring property, and the like, and has great importance on aspects of fish inheritance breeding and biological evolution researches.
Owner:HUNAN NORMAL UNIVERSITY

Method of providing readily available cellular material derived from peripheral blood, and a composition thereof

The present invention is directed to the process of preparing an expanded peripheral blood stem cell composition, preparing a TVEMF-expanded peripheral blood stem cell composition, methods of producing the same, and to repair of tissue and / or function with expanded, and TVEMF-expanded, peripheral blood stem cells.
Owner:REGENETECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products